Will you use FeNO testing in all COPD patients to determine whether they are candidates for therapy with dupilumab?
If so, would this be a consideration in all patients regardless of active smoking status? FeNO in active smokers has been questioned, could this have accounted for the difference seen in treatment response of patients with higher or lower FeNO in the BOREAS trial?
Answer from: at Community Practice
I suspect high eosinophils will be used more often.
Sign in or Register to read more
Answer from: at Academic Institution
Yes, I already do this.